目的 探討氧化樟腦注射液聯(lián)合環(huán)磷腺苷葡胺治療心力衰竭的臨床療效。方法 選取2016年9月—2017年9月在哈爾濱醫(yī)科大學(xué)附屬第四醫(yī)院治療的心力衰竭患者86例，隨機(jī)分為對(duì)照組（43例）和治療組（43例）。對(duì)照組靜脈滴注環(huán)磷腺苷葡胺注射液，180 mg加入5%葡萄糖注射液500 mL，1次/d；治療組在對(duì)照組基礎(chǔ)上肌肉注射氧化樟腦注射液，2 mL/次，1次/d。兩組均治療2周。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者心功能指標(biāo)和血清細(xì)胞因子水平。結(jié)果 治療后，對(duì)照組和治療組臨床總有效率分別為83.72%和97.67%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組左室舒張末期內(nèi)徑（LVEDD）、左心室收縮末期容積（LVESV）和左心室收縮末期內(nèi)徑（LVESD）均顯著降低（P<0.05），左心室射血分?jǐn)?shù)（LVEE）顯著升高（P<0.05），且治療組心功能明顯優(yōu)于對(duì)照組（P<0.05）。治療后，兩組血清氨基末端腦鈉肽前體（NT-proBNP）、β內(nèi)啡肽（β-EP）、白細(xì)胞介素-1β（IL-1β）、肌鈣蛋白（cTnT）水平顯著降低（P<0.05），血管內(nèi)皮生長(zhǎng)因子（VEGF）和類胰島素一號(hào)增長(zhǎng)因子（IGF-1）水平顯著升高（P<0.05），且治療組上述血清細(xì)胞因子水平明顯優(yōu)于對(duì)照組（P<0.05）。結(jié)論 氧化樟腦注射液聯(lián)合環(huán)磷腺苷葡胺治療心力衰竭效果顯著，可有效改善患者心功能，降低機(jī)體炎癥反應(yīng)，從而降低心肌重塑風(fēng)險(xiǎn)。

Objective To investigate the clinical efficacy of Vitacamphorae Injection combined with meglumine adenosine cyclophosphate in treatment of heart failure. Methods Patients (86 cases) with heart failure in the Fourth Affiliated Hospital of Harbin Medical University from September 2016 to September 2017 were randomly divided into control (43 cases) and treatment (43 cases) groups. Patients in the control group were iv administered with Meglumine Adenosine Cyclophosphate Injection, 180 mg added into 5% glucose injection 500 mL, once daily. Patients in the treatment group were im administered with Vitacamphorae Injection on the basis of the control group, 2 mL/time, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the cardiac function indicators, and the serum cytokines levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 83.72% and 97.67%, respectively, and there were differences between two groups (P<0.05). After treatment, the LVEDD, LVESV and LVESD in two groups were significantly decreased (P<0.05), but LVEE was significantly increased (P<0.05), and the cardiac function in the treatment group was significantly better than that in the control group (P<0.05). After treatment, the serum NT-proBNP, cTnT, β-EP and IL-1β levels in two groups were significantly decreased (P<0.05), but VEGF and IGF-1 levels were significantly increased (P<0.05), and these serum cytokines levels in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Vitacamphorae Injection combined with meglumine adenosine cyclophosphate has remarkable clinical effect in treatment of heart failure, which can effectively improve the heart function and reduce the inflammatory response, reduce the risk of myocardial remodeling.

黑龍江省教育廳科學(xué)技術(shù)研究項(xiàng)目（12541506）